Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 214-220

  Hasselbalch, Hans Carl ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chronic inflammation; Essential thrombocythemia; Mutations; Myelofibrosis; Polycythemia vera; Promotor

Indexed keywords

ALPHA2 INTERFERON; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 1 INHIBITOR; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTIOXIDANT RESPONSIVE ELEMENT; CHRONIC INFLAMMATION; CLONAL EVOLUTION; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENE SWITCHING; GENOMIC INSTABILITY; HEMATOPOIETIC CELL; HUMAN; MALIGNANT TRANSFORMATION; MUTAGENESIS; MYELOFIBROSIS; OXIDATIVE STRESS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; STEM CELL NICHE; THROMBOCYTHEMIA; TUMOR MICROENVIRONMENT;

ANIMALS; BONE MARROW NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHRONIC DISEASE; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; INFLAMMATION; JANUS KINASE 2; MUTAGENESIS; MUTATION; NEOPLASMS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; SIGNAL TRANSDUCTION; STEM CELL NICHE; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84872424841     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.10.020     Document Type: Review

References (100)

1. Campbell P.J., Green A.R. Mechanisms of disease: the myeloproliferative disorders. N Engl J Med 2006, 355(23):2452-2466.
2. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
3. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Massé A., et al. TET2 mutations in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
4. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42:722-726.
5. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
6. Oh S.T., Simonds E.F., Jones C., Hale M.B., Goltsev Y., Gibbs K.D., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116:862-864.
7. Klampfl T., Harutyunyan A., Berg T., Gisslinger B., Schalling M., Bagienski K., et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011, 118(July 7 (1)):167-176.
8. Rumi E., Harutyunyan A., Elena C., Pietra D., Klampfl T., Bagienski, et al. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol 2011, 86(12):974-979.
9. Barbui T., Carobbio A., Finazzi G., Vannucchi A.M., Barosi G., Antonioli E., et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011, 96(2):315-318.
10. Landolfi R., Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica 2011, 96(2):183-186.
11. Hasselbalch H.C. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?. Blood 2012, 119(14):3219-3225.
12. Vannucchi A.M., Masala G., Antonioli E., Chiara Susini M., Guglielmelli P., Pieri L., et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009, 18(7):2068-2073.
13. Frederiksen H., Farkas D.K., Christiansen C.F., Hasselbalch H.C., Sørensen H.T. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011, 118(25):6515-6520.
14. Dvorak H.F. Tumors: wounds that do not heal, Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315(26):1650-1659.
15. Hasselbalch H.C. Idiopathic myelofibrosis. Clinical aspects and studies on extracellular matrix metabolism. Dan Med Bull 1993, 40(1):39-55.
16. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357(9255):539-545.
17. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
18. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5(10):749-759.
19. Hussain S.P., Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121(11):2373-2380.
20. Mantovani A., Garlanda C., Allavena P. Molecular pathways and targets in cancer-related inflammation. Ann Med 2010, 42(3):161-170.
21. Hahn M.A., Hahn T., Lee D.H., Esworthy R.S., Kim B.W., Riggs A.D., et al. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 2008, 10280-10289.
22. Bogani C., Ponziani V., Guglielmelli P., Desterke C., Rosti V., Bosi A., et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 2008, 26(8):1920-1930.
23. Fourouclas N., Li J., Gilby D.C., Campbell P.J., Beer P.A., Boyd E.M., et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 2008, 93(November (11)):1635-1644.
24. Barrio S., Gallardo M., Albizua E., Jimenez A., Rapado I., Ayala R., et al. Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation. J Clin Pathol 2011, 64(11):1010-1013.
25. Vannucchi A.M., Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica 2011, 96(10):1398-1402.
26. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
27. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
28. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008, 118:560-570.
29. Kujawski M., Kortylewski M., Lee H., Herrmann A., Kay H., Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008, 118:3367-3377.
30. Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A.S., Nizet V. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453:807-811.
31. Hartnett L., Egan L.J., Inflammation DNA methylation and colitis-associated cancer. Carcinogenesis 2012, 33(4):723-731.
32. Grivennikov S.I., Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010, 21:11-19.
33. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
34. Heinrich P.C., Behrmann I., Müller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998, 334(Pt 2):297-314.
35. Li Y., de Haar C., Chen M., Deuring J., Gerrits M.M., Smits R., et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010, 59:227-235.
36. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 2003, 100:14133-14138.
37. Glauben R., Batra A., Fedke I., Zeitz M., Lehr H.A., Leoni F., et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006, 176:5015-5022.
38. Saito S., Kato J., Hiraoka S., Horii J., Suzuki H., Higashi R., et al. DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm Bowel Dis 2011, 17:1955-1965.
39. Foran E., Garrity-Park M.M., Mureau C., Newell J., Smyrk T.C., Limburg P.J., et al. Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6 Mo. Cancer Res 2010, 8:471-481.
40. Kominsky D.J., Keely S., MacManus C.F., Glover L.E., Scully M., Collins C.B., et al. An endogenously anti-inflammatory role for methylation in mucosal inflammation identified through metabolite profiling. J Immunol 2011, 186:6505-6514.
41. O'Hagan H.M., Wang W., Sen S., Destefano Shields C., Lee S.S., Zhang Y.W., et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands. Cancer Cell 2011, 20:606-619.
42. Bartsch H., Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 2006, 391:499-510.
43. Cooke M.S., Evans M.D., Dizdaroglu M., Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003, 17:1195-1214.
44. Ferguson L.R. Chronic inflammation and mutagenesis. Mutat Res 2010, 690:3-11.
45. Giustarini D., Dalle-Donne I., Tsikas D., Rossi R. Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci 2009, 241-281.
46. Simonelli V., Mazzei F., D'Errico M., Dogliotti E. Gene susceptibility to oxidative damage: from single nucleotide polymorphisms to function. Mutat Res 2012, 731:1-13.
47. Kristinsson S.Y., Björkholm M., Hultcrantz M., Derolf Å.R., Landgren O., Goldin L.R. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011, 29(21):2897-2903.
48. Austin C. Does oxidative damage contribute to the generation of leukemia?. Leuk Res 2009, 33:1297.
49. Erkeland S.J., Palande K.K., Valkhof M., Gits J., Danen-van Oorschot A., Touw I.P. The gene encoding thioredoxin-interacting protein (TXNIP) is a frequent virus integration site in virus-induced mouse leukemia and is overexpressed in a subset of AML patients. Leuk Res 2009, 33(10):1367-1371.
50. Fleischman A.G., Aichberger K.J., Luty S.B., Bumm T.G., Petersen C.L., Doratotaj S., et al. Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011, 118(24):6392-6398.
51. Hermouet S., Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?. Haematologica 2011, 96(11):1575-1579.
52. Naka K., Muraguchi T., Hoshii T., Hirao A. Regulation of reactive oxygen species and genomic instability in hematopoietic stem cells. Antioxid Redox Signal 2008, 10:1883-1894.
53. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007, 128:325-339.
54. Ito K., Hirao A., Arai F., Matsuoka S., Takubo K., Hamaguchi, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004, 431:997-1002.
55. Jang Y.Y., Sharkis S.J. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 2007, 110:3056-3063.
56. Merchant A.A., Singh A., Matsui W., Biswal S. The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels. Blood 2011, 118(25):6572-6579.
57. Trachootham D., Lu W., Ogasawara M.A., Nilsa R.D., Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008, 10(8):1343-1374.
58. Giles G.I. The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 2006, 12(34):4427-4443.
59. Tothova Z., Gilliland D.G. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 2007, 1(2):140-152.
60. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat Med 2005, 11(12):1306-1313.
61. Yalcin S., Zhang X., Luciano J.P., Mungamuri S.K., Marinkovic D., Vercherat C., et al. Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. J Biol Chem 2008, 283(37):25692-25705.
62. Toshihiko T., Matsui W. Development of maintenance of cancer stem cells under chronic inflammation. J Nippon Med Sch 2011, 78(3):138-145.
63. Barzilai A., Rotman G., Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst) 2002, 1(1):3-25.
64. Naka K., Hoshii T., Muraguchi T., Tadokoro Y., Ooshio T., Kondo Y., et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010, 463(7281):676-680.
65. Miyamoto K., Araki K.Y., Naka K., Arai F., Takubo K., Yamazaki S., et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007, 1(1):101-112.
66. Bakker W.J., Harris I.S., Mak T.W. FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell 2007, 28(6):941-953.
67. Kim J., Cha Y.N., Surh Y.-J.Y.J. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res 2010, 690:12-23.
68. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 428-435.
69. Ferguson L.R., Laing W.A. Chronic inflammation, mutation and human disease. Mutat Res 2010, 690:1-2.
70. Rushworth S.A., Bowles K.M., MacEwan D.J. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res 2011, 71(March 1 (5)):1999-2009.
71. Li J., Sejas D.P., Zhang X., Qiu Y., Nattamai K.J., Rani R., et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest 2007, 117(11):3283-3295.
72. Hasselbalch H.C. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer-time to change our therapeutic attitude with early upfront treatment?. Leuk Res 2009, 33(1):11-18.
73. Boyd M.T., Maclean N., Oscier D.G. Detection of retrovirus in patients with myeloproliferative disease. Lancet 1989, 1(8642):814-817.
74. Morgan D., Brodsky I. Human endogenous retrovirus (HERV-K) particles in megakaryocytes cultured from essential thrombocythemia peripheral blood stem cells. Exp Hematol 2004, 32(6):520-525.
75. Skov V., Larsen T.S., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., et al. Whole Blood Transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol 2011, 87(1):54-60.
76. Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol [Epub ahead of print].
77. Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res [Epub ahead of print].
78. Silver R.T. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006, 107(3):451-458.
79. Kiladjian J.J., Cassinat B., Turlure P., Cambier N., Roussel M., Bellucci S., et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006, 108(6):2037-2040.
80. Jabbour E., Kantarjian H., Cortes J., Thomas D., Garcia-Manero G., Ferrajoli A., et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007, 110(9):2012-2018.
81. Kiladjian J.J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112(8):3065-3072.
82. Quintás-Cardama A., Kantarjian H., Manshouri T., Luthra R., Estrov Z., Pierce S., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009, 27(32):5418-5424.
83. Larsen T.S., Møller M.B., de Stricker K., Nørgaard P., Samuelsson J., Marcher C., et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha interferon2b in polycythemia vera: a report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009, 14:331-334.
84. Turlure P., Cambier N., Roussel M., Belluci S., Zini J.M., Rain J.D., et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon {alpha}-2a (peg-IFN{alpha}-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial. Blood (ASH Annual Meeting Abstracts) 2011, 118(21):280.
85. Gowin K, Thapaliya P, Samuelsson J, Harrison C, Radia D, Andreasson B, et al. Experience with pegylated Interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012 [Epub ahead of print].
86. Kiladjian J.J., Chomienne C., Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008, 22(11):1990-1998.
87. Hasselbalch H.C., Larsen T.S., Riley C.H., Jensen M.K., Kiladjian J.J. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 2011, 12(3):392-419.
88. Hasselbalch H.C. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011, 4(6):637-655.
89. Kiladjian J.J., Mesa R.A., Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011, 117(18):4706-4715.
90. You H., Ding W., Rountree C.B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51:1635-1644.
91. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
92. Martin M., Herceg Z. From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med 2012, 4(January 31 (1)):8.
93. Nexø B.A., Christensen T., Frederiksen J., Møller-Larsen A., Oturai A.B., Villesen P., et al. The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1. PLoS ONE 2011, 6:e16652.
94. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363(12):1117-1127.
95. Hasselbalch H.C., Riley C.H. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?. Leuk Res 2006, 30(10):1217-1225.
96. Griner L.N., McGraw K.L., Johnson J.O., List A.F., Reuther G.W. A mechanistic rationale for the use of statins to enhance JAK2 inhibitor therapy in MPNs. Blood (ASH Annual Meeting Abstracts) 2011, 118. [Abstract 2816].
97. Essers M.A., Offner S., Blanco-Bose W.E., Waibler Z., Kalinke U., Duchosal M.A., et al. IFNa activates dormant haematopoietic stem cells in vivo. Nature 2009, 7240:904-908.
98. Plo I., Nakatake M., Malivert L., de Villartay J.P., Giraudier S., Villeval J.L., et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008, 112(4):1402-1412.
99. Riley C.H., Jensen M.K., Brimnes M.K., Hasselbalch H.C., Bjerrum O.W., Straten P.T., et al. Increased in ciculating CD+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myelopoliferative neoplasms during treatment with IFN-α. Blood 2011, 118(8):2170-2173.
100. Vannucchi A.M., Guglielmelli P., Rambaldi A., Bogani C., Barbui T. Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med 2009, 13(8A):1437-1450.